Document Detail


The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients.
MedLine Citation:
PMID:  21421014     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Exogenous Glucagon-Like Peptide-2 (GLP-2) treatment improves intestinal wet weight absorption in short bowel syndrome (SBS) patients. In healthy subjects, administration of GLP-2 increases small intestinal blood flow. The aim of the study was to evaluate the effect of GLP-2 on mesenteric blood flow and dynamic changes in cardiac parameters in SBS patients with jejunostomy and varying length of remnant small intestine. METHODS: 8 SBS patients with end-jejunostomy and less than 200 centimetres (cm) small intestine were given GLP-2, 1600μg subcutaneously (SC), or isotonic saline in a double blinded manner. At 0, 30 and 60 minutes plasma GLP-2 was measured, and from 0 to 90 minutes (min), blood flow in the superior mesenteric artery (SMA) and the celiac artery (CA) was measured using Doppler ultrasound (US), and cardiovascular variables were measured by continuous impedance cardiography and finger plethysmography. RESULTS: Plasma GLP-2 concentrations increased significantly in the GLP-2 group, whereas no changes were seen in the placebo group. Compared to baseline, GLP-2 SC elicited a 19.4 % decrease (p<0.01) in the resistance index (RI) and a 97.6 % increase in time averaged maximal velocity (TAMV) in the SMA (P<0.01). In the CA there were no significant changes in RI or TAMV in the GLP-2 or placebo group. Blood flow and length of remaining intestine were correlated (RI: y=0.14+4.3, R=0.83, p=0.01 and TAMV: y=1.21+21.3, R=0.63, p=0.09). GLP-2 non significantly increased cardiac output (CO), stroke volume (SV) and significantly increased heart rate (HR) compared to baseline. CONCLUSION: Subcutaneous GLP-2 increased SMA blood flow in end-jejunostomy SBS patients with less than 200 cm of remaining small intestine. The increase in blood flow correlated with the length of remaining intestine, suggesting that the increase is coupled to the metabolic actions of GLP-2 on the gut rather than effects on the vasculature.
Authors:
Lasse Bremholm; Mads Hornum; Ulrik B Andersen; Bolette Hartmann; Jens Juul Holst; Palle Bekker Jeppesen
Related Documents :
19841204 - Identification of potential markers in blood for the development of subclinical and cli...
20478284 - High selenium status in individuals exposed to arsenic through coal-burning in shaanxi ...
15157944 - Effects of garlic extract consumption on blood lipid and oxidant/antioxidant parameters...
18333764 - Importance of vacuum for breastmilk expression.
10966274 - Accuracy of base excess--an in vitro evaluation of the van slyke equation.
23740374 - Pharmacokinetic analysis of [(18)f]faza in non-small cell lung cancer patients.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-3-18
Journal Detail:
Title:  Regulatory peptides     Volume:  -     ISSN:  1873-1686     ISO Abbreviation:  -     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-3-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8100479     Medline TA:  Regul Pept     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2010. Published by Elsevier B.V.
Affiliation:
Department of Gastroenterology, Køge Hospital, University of Copenhagen.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Patterns of Avoidance Behaviours in the Light/Dark Preference Test in Young Juvenile Zebrafish: A Ph...
Next Document:  Vascular tissue engineering: Towards the next generation vascular grafts.